RNA, U7 small nuclear 12 pseudogeneGenealiases: RNU7-100P · U7.12
Q-omics provides the consensus-scored RNU7-12P profile across patient tissues and cancer cell-line models. RNU7-12P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RNU7-12P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU7-12P RNA expression shows 5,481 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, and STAD as cancer lineages where RNU7-12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-12P survival associations across molecular data types. RNU7-12P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-12P RNA expression–survival associations across cancer types. High RNU7-12P expression shows unfavorable associations in OV, READ, UCEC, LIHC, ESCA and PAAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for RNU7-12P RNA expression.
This table summarizes RNU7-12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-12P shows lower tumor expression in COAD and higher tumor expression in STAD and BLCA. The STAD box plot shows higher RNU7-12P RNA expression in tumor versus normal tissue (log2 FC = +0.814, t-test p < 0.001).
This table shows molecular features associated with RNU7-12P in patient tissues and cancer cell lines. In patient samples, RNU7-12P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
